Business · 16/04/2026Updated: 10/16/2026 · 1 min read
FDA Approves AREXVY Respiratory Syncytial Virus Vaccine for Rare Pediatric Disease Priority Review Voucher
Summary
The FDA has approved AREXVY, a Respiratory Syncytial Virus Vaccine, for a rare pediatric disease priority review voucher, following its June 7, 2024, BLA supplement approval.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →